NCT07429851 CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
| NCT ID | NCT07429851 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | Neuroendocrine Carcinoma of Lung |
| Study Type | OBSERVATIONAL |
| Enrollment | 34 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 34 participants in total. It began in 2026-01-01 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 \> 20%). The objective of this retrospective single-centre translational study will be to explore whether patients differ clinically in terms of diagnosis and treatment management. Currently, well differentiated high grade pulmonary NETs are managed using extrapolated algorithms from duodeno-pancreatic NETs, underlining a significant unmet clinical need. This is likely due to the rarity, uncertain pathological and molecular classification, and heterogeneous clinical course of well differentiated high grade pulmonary NETs. In this study a retrospective data-base of pulmonary, thymic and duodeno-pancreatic NETs with Ki-67 \> 20% will be created in order to analyze diagnostic and therapeutic pathways, clinical outcomes, imaging, disease evolution and molecular profiling. This study will adopt a hypothesis-generating approach to explore whether patients in these distinct groups differ clinically in terms of diagnosis and treatment management.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed diagnosis of well-differentiated high grade neuroendocrine tumor (Ki-67 \> 20% according to WHO 2022) performed or reviewed by a NEN-dedicated pathologist. * Primary tumor site:thyme, lung and duodenum-pancreas NETs. * Advanced stage of tumor disease and Any number of lines of therapy * Sufficient available clinical data on diagnosis, treatments, outcomes. Exclusion Criteria: * Poorly differentiated neuroendocrine carcinomas (NECs), GEP NET G1/G2, pulmonary carcinoid with Ki-67 \< 20%. * Diagnosis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) * Inadequate or unavailable tumor tissue for molecular analysis. * Incomplete clinical records or follow-up. * Other primary sites, except lung or pancreas.
Contact & Investigator
Nicola Fazio, MD
PRINCIPAL INVESTIGATOR
IEO
Frequently Asked Questions
Who can join the NCT07429851 clinical trial?
This trial is open to participants of all sexes, studying Neuroendocrine Carcinoma of Lung. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07429851 currently recruiting?
Yes, NCT07429851 is actively recruiting participants. Contact the research team at divisione.gastrointestinale@ieo.it for enrollment information.
Where is the NCT07429851 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT07429851 clinical trial?
NCT07429851 is sponsored by European Institute of Oncology. The principal investigator is Nicola Fazio, MD at IEO. The trial plans to enroll 34 participants.